Background: Although neurogenic inflammation via the activation of C fibers in the airway must have an important role in the pathogenesis of asthma, their regulatory mechanism remains uncertain. Objective: The pharmacological profiles of endogenous cannabinoid receptor agonists on the activation of C fibers in airway tissues were investigated and the mechanisms how cannabinoids regulate airway inflammatory reactions were clarified. Methods: The effects of endogenous cannabinoid receptor agonists on electrical field stimulation-induced bronchial smooth muscle contraction, capsaicin-induced bronchoconstriction and capsaicin-induced substance P release in guinea pig airway tissues were investigated. The influences of cannabinoid receptor antagonists and K+ channel blockers to the effects of cannabinoid receptor agonists on these respiratory reactions were examined. Results: Both endogenous cannabinoid receptor agonists, anandamide and palmitoylethanolamide, inhibited electrical field stimulation-induced guinea pig bronchial smooth muscle contraction, but not neurokinin A-induced contraction. A cannabinoid CB2 antagonist, SR 144528, reduced the inhibitory effect of endogenous agonists, but not a cannabinoid CB1 antagonist, SR 141716A. Inhibitory effects of agonists were also reduced by the pretreatment of large conductance Ca2+-activated K+ channel (maxi-K+ channel) blockers, iberiotoxin and charybdotoxin, but not by other K+ channel blockers, dendrotoxin or glibenclamide. Anandamide and palmitoylethanolamide blocked the capsaicin-induced release of substance P-like immunoreactivity from guinea pig airway tissues. Additionally, intravenous injection of palmitoylethanolamide dose-dependently inhibited capsaicin-induced guinea pig bronchoconstriction, but not neurokinin A-induced reaction. However, anandamide did not reduce capsaicin-induced guinea pig bronchoconstriction. Conclusions: These findings suggest that endogenous cannabinoid receptor agonists inhibit the activation of C fibers via cannabinoid CB2 receptors and maxi-K+ channels in guinea pig airways.

Barnes PJ: Neuroeffector mechanisms: the interface between inflammation and neuronal responses. J Allergy Clin Immunol 1996;98:S73–S83.
Joos GF, Pauwels RA: Tachykinin receptor antagonists: potential in airways diseases. Curr Opin Pharmacol 2001;1:235–241.
Murai M, Morimoto H, Maeda Y, Fujii T: Effects of the tripeptide substance P antagonist, FR 113680, on airway constriction and airway edema induced by neurokinins in guinea-pigs. Eur J Pharmacol 1992a;217:23–27.
Murai M, Morimoto H, Maeda Y, Kiyotoh S, Nishikawa M, Fujii T: Effects of FK 224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerve stimulation in guinea-pigs. J Pharmacol Exp Ther 1992b;262:403–408.
Morimoto H, Yamashita M, Matsuda A, Miyake H, Fujii T: Effects of FR 113680 and FK 224, novel tachykinin antagonists, on cigarette smoke-induced rat tracheal plasma extravasation. Eur J Pharmacol 1992;224:1–5.
Yoshihara S, Chan B, Yamawaki I, Pierangelo G, Ricciardolo FLM, Massion PP, Nadel JA: Plasma extravasation in the rat trachea induced by cold air is mediated by tachykinin release from sensory nerves. Am J Respir Crit Care Med 1995;151:1011–1017.
Ono M, Abe T, Watanabe M, Yamada Y, Yoshihara S: Nedocromil sodium inhibits hypertonic saline-induced plasma extravasation in guinea-pig airways. Biomed Res 1999;20:233–238.
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816–824.
Morimoto H, Matsuda A, Ohori M, Fujii T: Effects of ω-conotoxin GVIA on the activation of capsaicin-sensitive afferent sensory nerves in guinea pig airway tissues. Jpn J Pharmacol 1996;71:161–166.
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG: International union of pharmacology. 27. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161–202.
Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of peripheral receptor for cannabinoids. Nature 1993;365:61–65.
Glass M, Dragunow M, Faull RL: Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997;77:299–318.
Griffin G, Fernando SR, Ross RA, Mckay NG, Ashford ML, Shire D, Huffman JW, Yu S, Lainton JA, Pertwee RG: Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997;339:53–61.
Howlett AC, Johnson MR, Melvin LS, Mine GM: Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 1988;33:297–302.
Mackie KY, Westenbroek LR, Mitchell R: Cannabinoid activate an inwardly rectifying potassium conductance and inhibit Q-type cannabinoid receptor. J Neurosci 1995;15:6552–6561.
Caulfield MP, Brown DA: Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992;106:231–232.
Mackie K, Hille B: Cannabinoid inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992;89:3825–3829.
Fox AJ, Barnes PJ, Venkatesan P, Belvisi MG: Activation of large conductance potassium channels inhibits the afferent and efferent function of airway sensory nerves in the guinea pig. J Clin Invest 1997;99:513–519.
Ray NJ, Jones AJ, Keen P: Morphine, but not sodium cromoglycate, modulates the release of substance P from capsaicin-sensitive neurones in the rat trachea in vitro. Br J Pharmacol 1991;102:797–800.
Wu P, Penman E, Coy DH, Rees LH: Evidence for direct production of somatostatin-14 from a larger precursor than somatostatin-28 in a phaeochromocytoma. Regul Pept 1983;5:219–233.
Mulkey RM, Zucker RS: Action potentials must admit calcium to evoke transmitter release. Nature 1991;350:153–155.
Saria A, Martling CR, Yan Z, Theodorsson-Norheim E, Gamse R, Lundberg JM: Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation. Am Rev Respir Dis 1988;137:1330–1335.
Franco-Cereceda A, Saria A, Lundberg JM: Differential release of calcitonin-gene related peptide and neuropeptide Y from the isolated heart by capsaicin, ischemia, nicotine, bradykinin and ouabain. Acta Physiol Scand 1989;135:173–187.
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946–1949.
Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z: The peripheral cannabinoid receptor: adenylatecyclase inhibition and G protein coupling. FEBS Lett1995;375:143–147.
Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Casellas P, Ferrara P, Le Fur G: Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 1996;278:871–878.
Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME: Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5′-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther 1998;285:553–560.
Partwee RG: Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999;6:635–664.
Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA: Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993;90:7656–7660.
Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R: Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 1993;61:352–355.
Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995;92:3376–3380.
Tucker RC, Kagaya M, Page CP, Spina D: The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways. Br J Pharmacol 2001;132:1127–1135.
Aloe L, Leon A, Levi-Montalcini R: A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 1993;39:C145–C147.
Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A: N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996;300:227–236.
Abood ME, Martin BR: Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol 1996;39:197–221.
Lambert DM, Di Marzo V: The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 1999;6:757–773.
Calignano A, La Rana G, Piomelli D: Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide. Eur J Pharmacol 2001;419:191–198.
Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G: Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 2002;135:181–187.
Miura M, Inoue H, Ichinose M, Kimura K, Katsumata U, Takishima T: Effect of nonadrenergic noncholinergic inhibitory nerve stimulation on the allergic reaction in cat airways. Am Rev Respir Dis 1990;141:29–32.
Miura M, Ichinose M, Kimura K, Katsumata U, Takahashi T, Inoue H, Takishima T: Dysfunction of nonadrenergic noncholinergic inhibitory system after antigen inhalation in actively sensitized cat airways. Am Rev Respir Dis 1992;145:70–74.
Friedman MM, Kaliner MA: Human mast cells and asthma. Am Rev Respir Dis 1987;135:1157–1164.
Cook SA, Welch SP, Lichtman H, Martin BR: Evaluation of cAMP involvement in cannabinoid-induced antinociception. Life Sci 1995;56:2049–2056.
Holzer P: Local effector function of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988;24:739–768.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.